Biotechnology companies rely heavily on alliances with pharmaceutical companies to finance their research and development expenditures, and pharmaceutical firms rely heavily on alliances to supplement their internal research and development. Previous studies suggest that asymmetric information...

Most European Member States, particularly the former EU15 countries, have national systems providing universal access to health care, including pharmaceuticals. Given pressure on public budgets and rising expenditure for healthcare, national governments have introduced mechanisms to regulate...

This study analyzes the effect of pharmaceutical price regulation on delays in new drug launches. Because low price in one market may 'spill-over' to others, though parallel trade and external referencing, manufacturers may rationally prefer longer delay or non-launch to accepting a low price....

This examination of the economics of the biopharmaceutical industry has 18 chapters by health economists. Part 1 examines the economics of biopharmaceutical innovation. Part 2 examines the market for biopharmaceuticals with chapters on prices and reimbursement in industrialised and developing...